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Introduction:  Several  studies  towards  the  development  of an  effective  treatment  for intestinal  mucositis
have  been  reported,  since  this  condition  represents  a major  problem  in  clinical  oncology  practice  due  to
cytotoxic  effects  of  chemotherapy.  However  standardized  protocols  and  universally  accepted  treatment
options  are  yet  to be  established.
Objectives:  Given  above,  this  study  evaluated  the  protective  effects  of  a mucoadhesive  formulation  con-
taining  both  Bidens  pilosa  L.  (Asteraceae)  (BP)  and  curcuminoids  from  Curcuma  longa  L.  (Zingiberaceae)
(CL)  on  intestinal  mucositis  induced  by  5-ﬂuoruoacil  (5-FU)  in  mice.
Results:  As  expected,  animals  only  treated  with  5-FU (200 mg/kg)  showed  a signiﬁcant  reduction  of
60.3  and  42.4%  in villi  and  crypts  size,  respectively,  when  compared  to  control.  On  the  other  hand,
the  proposed  therapeutic/prophylactic  treatment  with  mucoadhesive  formulations  managed  to reduce
histopathologic  changes  in mice  bearing  mucositis,  especially  at 125  mg/kg  BP  +  15  mg/kg CL  dose.  The
formulation  promoted  an  increase  of  275.5%  and  148.7%  for villi  and  crypts  size, respectively.  Moreover,
chemotherapy-related  weight  loss  was reduced  by  7.4%  following  the treatment.  In  addition,  an  increase
of  10  and  30.5%  in  red  and  white  blood  cells  was  observed  when  compared  to  5-FU group.  Furthermore,
treatments  with  the mucoadhesive  formulation  containing  BP/CL up  modulated  Ki-67  and  Bcl-2  expres-
sion while  reduced  pro-apoptotic  regulator  Bax.  The  formulation  also  modulated  inﬂammatory  response
triggered  by  5-FU  through  reduction  of 68%  of  myeloperoxidase  activity  and  a 4-fold  increase  in  anti-
inﬂammatory  IL-10  levels.  In  parallel,  the  oxidative  stress  via  lipid peroxidation  was  reduced  as  indicated
by  decrease  of  63% of  malondialdehyde  concentrations.  Additionally,  the  new  formulation  presented  low
acute  oral  systemic  toxicity,  being  classiﬁed  in  the category  5 (2000  mg/kg  < LD50 < 5000  mg/kg)  of the
Globally  Harmonized  Classiﬁcation  System.
Conclusions:  This  study  showed  an interesting  potential  of  the  mucoadhesive  formulation  of  BP/CL  for
the  treatment  of  5-FU-induced  intestinal  mucositis.  Given  the  perspectives  for the  development  of a  new
medicine,  clinical  studies  are  in  progress  to better  understand  the  protective  effects  of  this  innovative
formulation  in  treating  mucositis.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC∗ Corresponding author at: Faculdade de Farmácia, Universidade Federal de Goiás,
ua 240 esquina com 5a Avenida, s/n, Setor Universitário, Goiânia, GO CEP: 74605
70,  Brazil. Fax: +55 62 3209 6039x202.
E-mail address: marizecv@ufg.br (M.C. Valadares).
ttp://dx.doi.org/10.1016/j.toxrep.2015.10.013
214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. IntroductionIntestinal mucositis represents a major problem in clini-
cal oncology practice due to cytotoxic effect associated with
chemotherapy [1]. This pathological condition is correlated with
events such as apoptosis, epithelial hypoproliferation, crypts/villi
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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ize decreasing, inﬂammatory inﬁltrate, increased expression of
NF-, IL-1 and IL-6, with consequent changes in the intesti-
al absorptive capacity and bacterial colonization [2]. Mucositis is
lso frequently associated with abdominal pain, diarrhea, vomit-
ng and nausea [3,4]. Additionally, mucositis is the cause of patient
onger hospitalization, raising the total cost of the treatment which
ecomes an economical and public health problem [5]. Although
everal studies have already been conducted in attempts to treat
ucositis, there are still no universally accepted and standard-
zed protocols for the treatment. Substances of natural origin have
een recently studied in this context, especially those with anti-
nﬂammatory and anti-oxidant properties such as Bidens pilosa L.
Asteraceae) (BP) and Curcuma longa L. (Zingiberaceae) (CL).
BP is a plant present in tropical and sub-tropical regions, widely
sed in folk medicine with an extensive phytochemical consti-
ution [6,7]. In addition to anti-inﬂammatory and anti-oxidant
ffects, several pharmacological activities related to BP have been
eported such as anti-hypertensive, anti-hyperglycemic, antiulcer,
mmunosuppressive, hepatoprotective, antileukemic, antimalarial
nd antibacterial [8,9]. Its efﬁcacy has been recently demon-
trated in vivo on gastric mucosal injury induced by hydrochloric
cid/ethanol in rats. Oral administration of BP exerted a pro-
ective effect in these lesions, which probably contributed to
he suppression of oxidative stress, prostaglandin production and
nﬂammation [10]. Recently, Ávila et al. [11], demonstrated that a
ucoadhesive formulation based on BP reduced intestinal injury
n mice caused by 5-ﬂuorouracil, in special the formulation led to
 reduction in the local inﬂammatory inﬁltrate.
CL and its compounds, especially curcumin, have shown impor-
ant anti-inﬂammatory and anti-oxidant properties, and have been
idely studied in cancer chemoprevention and suppression of
umor growth [12,13]. CL also showed immunomodulatory capac-
ty, exerting its effects by regulating the expression of several genes
nd proteins [14]. Moreover, previous study has demonstrated that
 formulation containing curcumin, -tocopherol and sunﬂower
il was effective in reducing radiation-induced ulceration of the
ral mucosa in rats [15]. Furthermore, a pilot study with pediatric
atients undergoing chemotherapy has highlighted the promis-
ng use of topical curcumin for prevention of oral mucositis [16].
revious work from our group showed that a mucoadhesive for-
ulation with curcuminoids from CL positively modulated Ki-67
rotein in villi and crypts epithelium of mucositis-bearing mice,
cting positively on the rate of intestinal cell proliferation [17].
In spite of the wide spectrum of biological effects of the
urcumin, its low oral bioavailability and poor water solubility
epresent a limiting factor for its therapeutic use. These limita-
ions have led to the development of various formulation strategies
o improve curcumin effects, such as mucoadhesive products.
ucoadhesion systems are based on polymeric compounds, which
ave the ability to adhere to the surface of cells, or to the mucus
ayer that covers the epithelium. These formulations are of great
harmaceutical interest due to their ability in prolonging the resi-
ence time of the drug at the absorption site. In addition, they can
romote a more intimate contact with the mucosa providing better
opical treatment [18,19]. In this regarding, previous work from our
roup showed that a mucoadhesive formulation of CL also attenu-
ted body weight loss and protected intestinal mucosa from villus
hortening and crypt deepening induced by 5-FU [17].
Previous data indicate that BP or CL alone treated intesti-
al mucositis through different mechanisms, reducing the local
nﬂammatory inﬁltrate and/or increasing the rate of intestinal cell
roliferation, respectively. Based on these ﬁndings, this study eval-
ated the protective effects of a mucoadhesive formulation based
n poloxamer 407, a tri-block copolymer with mucoadhesive prop-
rties, containing both BP/CL extracts in mice bearing intestinal
ucositis induced by 5-ﬂuorouracil (5-FU).eports 3 (2016) 279–287
2. Materials and methods
2.1. Chemicals
C. longa (>95% curcuminoid content) and B. pilosa glycolic
extracts (Ecobidens®) were obtained from GAMMA  (São Paulo,
SP, Brazil) and CHEMYUNION (Sorocaba, SP, Brazil), respectively.
Transcutol HP® (diethylene glycol monoethyl ether) was kindly
donated by Gattefossé (Lyon, France). Soluplus® HS15 (Macrogol-
15-hydroxystearate) was  kindly donated by Pharma Ingredients
and Services BASF (São Paulo, SP, Brazil). Polyethylene glycol
400 and sodium azide were acquired from Labsynth (Diadema,
SP, Brazil). Butylated hydroxytoluene and 3,3diaminobenzidine
(DAB) were obtained from Mapric (São Paulo, SP, Brazil) and
Dako (Carpinteria, CA, USA), respectively. 5-Fluorouracil, hexade-
cyltrimethylammonium bromide, tri-block copolymer poloxamer
407, bovine serum albumin (BSA), EDTA, phenylmethylsulfonyl ﬂu-
oride (PMSF), kallikrein inhibitor units of aprotinin A, n-butanol
and ortho-dianisidine were purchased from Sigma–Aldrich (St.
Louis, MO,  USA). ImmunoCruzTM mouse ABC staining systems
(sc-2017 and 2018), monoclonal mouse anti-mouse p53 (clone
3H2820), monoclonal mouse anti-human Bcl2 (clone C-2) and poly-
clonal rabbit anti-mouse Bax (clone P-19) antibodies were acquired
from Santa Cruz Biotechnology (Paso Robles, CA, USA); whereas
monoclonal mouse anti-human Ki-67 (clone 124) antibody were
obtained from Novacastra (Newcastle, UK). Mouse IL-10 BD Cyto-
metric Bead kit was purchased from BD Biosciences (San Diego, CA,
USA). Trichloroacetic acid, NaCl, Tween 20, benzethonium chloride,
H2O2, tris, HCl, methanol and xylene were obtained from Vetec (Rio
de Janeiro, RJ, Brazil). Thiobarbituric acid, hematoxylin and eosin
stainings were acquired from Merck (Darmstadt, HE, Germany).
Xylazine and ketamine were purchased from Syntec (Cotia, SP,
Brazil) and König (Santana de Parnaíba, SP, Brazil), respectively.
2.2. Preparation of mucoadhesive and non-mucoadhesive
formulations
The mucoadhesive formulation was  composed by CL (1%, m/m)
and BP (40%, v/v) extracts, tri-block copolymer poloxamer 407 (15%,
m/m),  Surplus® HS15 (3.2%, m/m),  Transcutol HP (10%, v/v), cit-
ric acid (to pH 4.5–6.0) and polyethylene glycol 400 as a liquid
vehicle. The non-mucoadhesive formulation was prepared without
poloxamer, which was replaced by PEG 400.
Formulations were prepared by mixing constituents in a heated
reactor (65–70 ◦C) under mechanical stirring. The pH of the ﬁnal
preparation was adjusted using citric acid. Once prepared, formu-
lations were placed in ambar ﬂasks and stored at room temperature
protected from light until use. The total polyphenol content
of the BP extract determined by the Folin Ciocalteau method
was 88.2 ppm of total polyphenols, which was within the range
(20–200 ppm) of the analysis certiﬁcate issued by the Ecobidens®
manufacturer. The total curcuminoid content of the formulations,
based on curcumin levels, was  evaluated by UV spectrophotometry
( = 425 nm).
2.3. Animals
Male Swiss mice (age: 8–10 weeks; weight: 35–40 g) were
obtained from the Bioterium at Federal University of Goiás, and
all efforts were conducted to ensure the animal welfare. Mice were
acclimatized for a week prior to the beginning of experiments and
kept under steady conditions with light–dark cycles and controlled
temperature, while water and food were provided ad libitum.
The experimental protocol (UFG no. 036/2012) was approved by
the Research Ethics Committee at this University. At the end of
each assay, animals were previously anesthetized by 10 mg/kg of
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ylazine and 100 mg/kg of ketamine hydrochloride administered
ntraperitoneally and euthanized by cervical dislocation [20].
.4. Experimental design
Mice (n = 5/group) were treated orally (gavage) with three
ifferent doses of mucoadhesive or non-mucoadhesive formu-
ations containing BP/CL for 6 days (days 1–6). The following
oses of both preparations were administered to the ani-
als: 75 mg/kg BP + 3.75 mg/kg CL; 100 mg/kg BP + 7.5 mg/kg CL;
25 mg/kg BP + 15 mg/kg CL. Additionally, two groups were treated
ith each formulation without BP/CL (blank formulations). On days
–6, intestinal mucositis was induced by intraperitoneal adminis-
ration of 5-FU (200 mg/kg), as described by Wu et al. [3]. On the 7th
ay, animals were anesthetized to perform blood collection by car-
iac puncture followed by euthanasia. A duodenal portion of about
0 cm was then harvested from each animal at approximately 3 cm
eyond the pyloric sphincter.
.5. Histological and morphometric analysis
The histomorphometric evaluation was conducted as described
y Ávila et al. [11]. Brieﬂy, the duodenum of each animal was
xed in 10% neutral buffered formalin solution for 24 h, sectioned,
utomatically processed (OMA DM-20, M20090257, São Paulo,
razil), embedded in parafﬁn and then sectioned with a microtome
Leica RM2165, Gottingen, Germany) in 5 m slices. The sections
ere stained using routine haematoxylin/eosin technique and
hen embedded in parafﬁn. Sections of 5 mm thick were deparaf-
nized, stained with hematoxylin-eosin (H&E) and examined under
n optical microscope (Zeiss Axioskop 40, Carl Zeiss, Gottingen,
ermany) to carry out the measuring of villi and crypts lengths
f ten random ﬁelds of each slide using AxioVision 40 software,
ersion 4.7.2.0 (Carl Zeiss, Jena, TH, Germany). To assess damage
everity of the intestinal mucositis, a semi-quantitative histopatho-
ogic evaluation was performed covering parameters obtained from
he blades. The evaluation was conducted in a triple-blinded assay
nd results indicate the mean scores of the three assessments. The
riteria used were as follows: inﬂammatory inﬁltration, epithe-
ial vacuolization, muscle layer integrity, epithelial integrity and
dema. These changes were then classiﬁed according to the fol-
owing scores: 0—normal, 1—mild (changes limited at basal third
f the lining epithelium), 2—moderate (when the changes repre-
ented two-thirds of the lining epithelium), 3—severe (more than
wo-thirds of the epithelium affected). The ﬁnal score was  obtained
y summing the scores of each characteristic in order to obtain a
nal score called histological damage index (HDI) and then a com-
arison among groups were performed. From these analyzes, the
ost effective dose of the formulations was chosen for subsequent
tudies.
.6. Mice body weight evaluation
Animals were weighed daily during 7 days, immediately before
he administration of chemotherapy or treatment. The percentage
f the variation in body mass of each group in this period was then
valuated day-to-day in relation to the initial weight.
.7. Hematological analysisHematological examination was performed using an ABX Micros
0 apparatus (Horiba, São Paulo, SP, Brazil) by red and white blood
ells counting.eports 3 (2016) 279–287 281
2.8. Immunohistochemistry
Analyses were carried out to evaluate the expression of Bcl2,
Bax, p53 and Ki-67 as described elsewhere [11]. Brieﬂy, 3 m thick
sections were prepared from different animal groups and immuno-
histochemistry was performed using Santa Cruz Biotechnology
(Paso Robles, CA, USA) kits. Primary antibodies were used as fol-
lows: Ki-67 at 1:100, Bcl-2 at 1:50, Bax at 1:50 and p53 at 1:50.
The labeled cells were then visualized by light microscopy (Zeiss
Axioskop 40, Carl Zeiss, Göttingen, Germany) at 20× and counted in
the epithelial layer and bowel inﬁltration. The percentages of posi-
tive cells for the proteins studied were determined by the analysis
of 10 consecutive ﬁelds (100 cells/ﬁeld).
2.9. Measurement of IL-10 cytokine
About 250 mg  of intestinal tissue was homogenized in 10 mL
of antiprotease solution (PBS-BSA buffer containing 0.1 mM
PMSF, 0.1 mM benzethonium chloride, 10 mM EDTA, 20 kallikrein
inhibitor units of aprotinin A and 0.05% Tween 20) in an ultra-
Turrax® T 25 digital (IKA, Baden-Württemberg, Germany) at
10,000 rpm for 5 min. Then, homogenates were centrifuged at
2000 rpm for 15 min  at 4 ◦C and supernatant was used for IL-10
quantiﬁcation by BD FACSCanto II ﬂow cytometer (BD Biosciences,
San Jose, CA, USA) using Mouse IL-10 BD Cytometric Bead kit (BD
Biosciences) in accordance with the manufacturer’s instructions.
2.10. Myeloperoxidase (MPO) activity
MPO  is an enzyme found primarily in neutrophil azurophilic
granules and it has been extensively used as a biochemical marker
for granulocyte inﬁltration. The extent of neutrophil accumulation
in the intestinal tissue was measured by MPO  activity evalua-
tion as previously described [21]. Brieﬂy, 250 mg of tissue was
homogenized in 5 mL  of potassium phosphate buffer (pH 7.2)
with hexadecyltrimethylammonium bromide (HTAB, 0.5%) in an
ultra-Turrax® T 25 digital (IKA, Baden-Württemberg, Germany)
at 10,000 rpm for 5 min. Then, homogenates were centrifuged at
2000 rpm for 15 min  at 4 ◦C. MPO  activity in the resuspended pel-
let was assayed by measuring the change in absorbance at 450 nm
using o-dianisidine dihydrochloride and 1% hydrogen peroxide.
Results were reported as MPO  units/100 mg of tissue × 1000.
2.11. Determination of lipid peroxidation
Lipid peroxidation products in the intestinal tissue were deter-
mined by measuring of malondialdehyde (MDA), thiobarbituric
acid reactive substance (TBARS), based on the method described
by Marques et al. [22] with some modiﬁcations. Brieﬂy, 250 mg
of intestinal tissue was homogenized in 5 mL  of potassium
phosphate buffer (pH 7.2) with hexadecyltrimethylammonium
bromide (HTAB, 0.5%) in an ultra-Turrax® T 25 digital (IKA,
Baden-Württemberg, Germany) at 10,000 rpm for 5 min. Then,
homogenates were centrifuged at 2000 rpm for 15 min  at 4 ◦C.
The supernatant obtained was used to determine the activity of
MDA. Then, 250 L of supernatant plus 25 L BHT butylated 4%
in methanol were homogenized in a vortex. Then 1 mL  of 12%
trichloroacetic acid (TCA), 1 mL  of 0.73% thiobarbituric acid (TBA)
and 750 L of Tris–HCl buffer were added and the reaction mixture
was heated at 95 ◦C for 60 min. After, the tubes were placed on ice
to block the reaction. After, 5 mL  of n-butanol was added and the
mixture was  shaken vigorously. After centrifugation at 5000 rpm
for 10 min, the n-butanol layer was taken and optical density read-
ing was  performed at 532 and 453 nm.  MDA concentrations were
obtained by subtracting 20% of the absorbance at 453 nm from
the absorbance at 532 nm using a molar extinction coefﬁcient of
282 C.C.C. Bastos et al. / Toxicology Reports 3 (2016) 279–287
Fig. 1. Morphometric evaluation of crypts (A) and villi (B) in small intestine of mucositis-bearing mice induced by 5-FU and its treatment with non-mucoadhesive or
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Table 1
Histological damage index (HDI) of the small intestinal samples of mucositis-bearing
mice (n = 5 per group) induced by 5-FU and its treatment with the mucoadhesive
formulation containing 125 mg/kg BP + 15 mg/kg CL. Pathological changes were clas-
siﬁed according to the following scores: 0–normal (no change), 1–mild, 2–moderate
and  3–severe changes.
Criteria Treatment groups
Control 5-FU 125 mg/kg
BP + 15 mg/kg CL + 5-FU
Inﬂammatory inﬁltrate 1.1 ± 0.3 2.9 ± 0.3c 2.0 ± 0.6c,e
Vacuolation 1.1 ± 0.3 2.0 ± 0.8a 1.8 ± 0.9
Muscular layer integrity 0.3 ± 0.5 1.4 ± 1.2a 0.1 ± 0.3b
Epithelium integrity 0.1 ± 0.3 1.7 ± 1.0c 0.6 ± 0.5d
Edema 0 0 0
HDI  0.5 ± 0.5 1.6 ± 0.9 0.9 ± 0.8
All data are expressed as mean ± SD of ﬁve animals per group. Signiﬁcantly different
at  p < 0.05.ucoadhesive formulations containing BP/CL. Formulation doses or blank formulati
ere  administered intraperitoneally from 4th to 6th day. On day 7, animals (n = 
orphometric analysis. (*p < 0.05 and ***p < 0.0001 vs. control; #p < 0.05 and ###p < 0
.56 × 105 M−1 cm−1. Data were reported as nmol MDA/mg of tis-
ue.
.12. Acute oral systemic toxicity
The analysis of acute oral toxicity was performed according to
ECD Guideline 420 – Acute Oral Toxicity – Fixed Dose Procedure
23]. Brieﬂy, after two hours of fasting, mice were randomly sepa-
ated and a single 2000 mg/kg dose of mucoadhesive formulation
as administrated orally (gavage) in each animal. After treatment,
linical observations were conducted at 5, 15 and 30 min, and each
our up to the twelfth hour of the ﬁrst day. Posteriorly, mice
ere examined once a day for an additional 13 days. From the
esults obtained, the mucoadhesive formulation was  then catego-
ized according to the Globally Harmonized Classiﬁcation (GHS)
ystem.
.13. Statistical analysis
Data are expressed as mean ± standard deviation. The inter
roup variation was measured by one or two-way Analysis of Vari-
nce (ANOVA) followed by Bonferroni test using a GraphPad Prism
ersion 5.01 software for Windows (San Diego, CA, USA). Statistical
igniﬁcance was considered when p < 0.05.
. Results
.1. Effects of the mucoadhesive formulation and
on-mucoadhesive of BP/CL on intestinal histomorphometric
nalysis in mice
As previously demonstrated, animals exposed only to 5-FU
200 mg/kg) showed a signiﬁcant reduction of 60.3 and 42.4% in
illi and crypts size, respectively, when compared to non-exposed
nimals (p < 0.0001), according to Fig. 1. In contrast, prophy-
actic/therapeutic treatments with both, non-mucoadhesive and
ucoadhesive formulations, for 6 days protected against 5-FU-
nduced intestinal damage. When compared to 5-FU group, there
as a signiﬁcant increase of crypts size of 72.6 (p < 0.001), 71.5
p < 0.001) and 90.5% (p < 0.0001) for non-mucoadhesive formu-
ation at 75 mg/kg BP + 3.75 mg/kg CL, 100 mg/kg BP + 7.5 mg/kg
L and 125 mg/kg BP + 15 mg/kg CL + 5-FU, respectively; while
or mucoadhesive formulation it was 71.6 (p < 0.001), 72.8
p < 0.001) and 148.7% (p < 0.0001), in the same concentrations. Inre administered orally (gavage) to mice over 6 days, while doses of 5-FU (200 mg/kg)
/group) were euthanized and the small intestine of each mice was collected for
 vs. 5-FU. One-way ANOVA and Bonferroni test).
relation to villi size, it was  was  observed a signiﬁcant increase
of 116.7 (p < 0.001), 120.2 (p < 0.001) and 210.5% (p < 0.0001)
for non-mucoadhesive formulation and 190.3 (p < 0.0001), 193.2
(p < 0.0001) and 275.5% (p < 0.0001) for mucoadhesive formulation
at 75 mg/kg BP + 3.75 mg/kg CL, 100 mg/kg BP + 7.5 mg/kg CL and
125 mg/kg BP + 15 mg/kg CL + 5-FU, respectively, in comparison to
5-FU group. As noted, mucoadhesive formulation resulted in bet-
ter protection of intestinal structures, especially at 125 mg/kg + BP
15 mg/kg CL dose, highlighting the potential of this technological
preparation against 5-FU-induced intestinal toxicity.
Corroborating these ﬁndings, histological analysis of the villi
and crypts showed protective effects of formulations, particu-
larly mucoadhesive formulation at 125 mg/kg + BP 15 mg/kg CL
dose (Fig. 2). This dose had greater efﬁcacy compared to non-
mucoadhesive formulations and showed histological damage index
(HDI) of 0.9, similar to control (HDI = 0.5), which was  56.2% lower
than 5-FU group (HDI = 1.6) (Table 1). Therefore, the mucoadhe-
sive formulation at 125 mg/kg + BP 15 mg/kg CL dose was  used for
subsequent assays.a p < 0.05.
b p < 0.01.
c p < 0.001 vs. control.
d p < 0.01.
e p < 0.001 vs. 5-FU. One way ANOVA and Bonferroni test.
C.C.C. Bastos et al. / Toxicology Reports 3 (2016) 279–287 283
Fig. 2. Effects of non-mucoadhesive or mucoadhesive formulations containing BP/CL on small intestinal histological damage of mucositis-bearing mice induced by 5-FU.
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erative activity in the intestine of healthy animals was observed,
probably due to a high intestinal tissue turnover. On  the other
hand, mucositis-bearing mice without treatment showed a reduced
expression of 32% in Ki-67 expression (p < 0.001) associated with
Fig. 3. Effects of the mucoadhesive formulation at 125 mg/kg + BP 15 mg/kg CL dose
on  the variation of corporal mass of mucositis-bearing mice induced by 5-FU. For-
mulation doses or blank formulation were administered orally (gavage) to mice overormulation doses or blank formulation were administered orally (gavage) to mice
th  to 6th day. On day 7, animals (n = 5 mice/group) were euthanized and the sma
epresentative of each treatment group.
.2. Effects of the mucoadhesive formulation of BP/CL in body
eight variation
According to previous results, control group showed an increase
f weight of about 13.1% throughout the experimental period. How-
ver, after 5-FU exposure, animals showed a signiﬁcant weight loss,
eaching a reduction about 15% of initial body weight in the seventh
ay (p < 0.001). Treatment based on the mucoadhesive formula-
ion at 125 mg/kg + BP 15 mg/kg CL dose resulted in a protection
gainst weight loss triggered by chemotherapy. In these animals,
he weight loss was reduced in 7.4% (p < 0.001) (Fig. 3).
.3. Effects of the mucoadhesive formulation of BP/CL in the
-FU-induced hematotoxicity
As shown in Fig. 4, 5-FU group showed a reduction of 18 and
1.2% (p < 0.01) in red and white blood cells, respectively, in com-
arison to control. Contrasting, treatment with the mucoadhesive
ormulation at 125 mg/kg + BP 15 mg/kg CL dose was able to pro-
ote an increase of 10 and 30.5% (p < 0.01), when compared to
-FU group, demonstrating the hematoprotective potential of the
ucoadhesive formulation.
.4. Effects of the mucoadhesive formulation of BP/CL on
ntestinal cell proliferation and apoptosis markers
In the immunohistochemistry analysis, the expression of mark-
rs Ki-67 (cell proliferation) and p53, Bax and Bcl-2 (apoptosis)
ere evaluated in mucositis bearing-mice, treated and non-treated
ith the test formulation (Fig. 5). In all groups, a predominant
xpression of nuclear staining for p53 and cytoplasmic staining6 days, while doses of 5-FU (200 mg/kg) were administered intraperitoneally from
stine of each mice was collected for morphometry analysis. Photomicrographs are
for Bax and Bcl-2 in intestinal villi and crypts was observed; while
both nuclear and cytoplasmic expression for Ki-67 was noted. In
control animals, normal levels of 96.6, 3.5 and 3.6% for Ki-67, Bax
and Bcl-2 markers, respectively, were present. An intense prolif-6  days, while doses of 5-FU (200 mg/kg) were administered intraperitoneally from
4th  to 6th day. Mice were weighed throughout 7 days of the experiment to obtain
the variation in body mass (%). Each point presents mean ± SD of animals (n = 5).
(*p < 0.05 and ***p < 0.001 vs. control; #p < 0.05 and ###p < 0.001 vs. 5-FU. Two-way
ANOVA and Bonferroni test).
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Fig. 4. Effects of the mucoadhesive formulation at 125 mg/kg + BP 15 mg/kg CL dose
in  blood cells. Formulation doses or blank formulation were administered orally
(gavage) to mice over 6 days, while doses of 5-FU (200 mg/kg) were administered
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mntraperitoneally from 4th to 6th day. On day 7, animals (n = 5 mice/group) were
nesthetized and the blood collected by cardiac puncture. (**p < 0.01 vs. control;
#p < 0.01 vs. 5-FU. Two-way ANOVA and Bonferroni test).
 high apoptosis ratio due to increased marking of 20.8% in pro-
poptotic regulator Bax (p < 0.001) versus a reduced expression of
% in anti-apoptotic Bcl-2 expression. Contrasting with these ﬁnd-
ngs, treatment with the mucoadhesive formulation was able to
odulate the rate of apoptosis and restore proliferative activity
f intestinal tissue in mucositis-bearing animals, since Ki-67, Bax
nd Bcl-2 expressions were 78 (p < 0.001), 8.7 (p < 0.01) and 8.5%
p < 0.001), respectively. Regarding to p53 levels, no statistically
igniﬁcant difference between groups was observed.
.5. Effects of the mucoadhesive formulation of BP/CL on the
nﬂammatory and oxidative stress response-induced by 5-FU
In the inﬂammatory response evaluation, animals exposed to
nly 5-FU showed a signiﬁcant increase of 191.7% (p < 0.0001) for
PO  activity associated with a decrease of 80.2% for IL-10 levels
p < 0.001), when compared to control (Fig. 6A, B). In parallel, 5-
U also promoted an increase of 124.6% of the oxidative stress via
ipid peroxidation as demonstrated by MDA  activity (p < 0.0001).
n contrast, values found for mucositis-bearing mice, treated
ith mucoadhesive formulation at 125 mg/kg BP + 15 mg/kg CL
ose, were close to those found in the control group. Therefore,
ucoadhesive formulation was signiﬁcantly able to restore these
arameters in relation to 5-FU group (p < 0.05) (Fig. 6A, B).
.6. Evaluation of acute oral systemic toxicity of the
ucoadhesive formulation of BP/CL
The exposure of animals to a single dose of 2000 mg/kg mucoad-
esive formulation of BP/CL was not able to trigger death or clinical
igns of toxicity throughout the experimental period (14 days).
n addition, macroscopic and histopathological analysis revealed
o abnormality induced by the formulation in the organs studied.
onsequently, the mucoadhesive formulation of BP and CL was  clas-
iﬁed in the category 5 (2000 mg/kg < LD50 < 5000 mg/kg) of GHS
ystem. Moreover, this formulation did not increase the frequency
f micronucleus (data not shown).
. Discussion
Many experimental therapeutic protocols for mucositis are
eing investigated [24,25]. Among them, the use of natural prod-
cts has stood out, given the range of phytochemicals that act in
ssociation and in multi-targeted manner to achieve the desired
rophylactic/therapeutic effect. In this study, we showed that a
ucoadhesive formulation containing BP/CL was  able to protecteports 3 (2016) 279–287
mice from 5-FU-induced intestinal injury by through modulating of
pro- and anti-apoptotic regulators, increasing of cell proliferation
rate in association with reduction of oxidative stress and inﬂam-
matory responses. The mucoadhesive property of the formulation
induced better protection of intestinal structures.
As mentioned before, the use of mucoadhesive formulation
based on poloxamer 407 seems an interesting pharmaceutical
strategy. Due to its rheological properties [26], this polyoxyethy-
lene copolymer can decrease the mucociliary clearance and
increase the contact time of the formulation with the intesti-
nal mucosa. Recently, it was  demonstrated that the incorporation
of BP glycolic extract [11] or curcuminoids from CL [17] in a
liquid formulation based on poloxamer 407 efﬁciently reduced
5-FU-induced intestinal injuries in mice, especially by anti-
inﬂammatory/antioxidant effects and/or restoration of intestinal
proliferative activity. Therefore, each of these preparations seems
to act on key cellular mechanisms of mucositis, inﬂammation and
overproduction of reactive oxygen species (ROS), through differ-
ent pathways. In this sense, the combined use of these plants in
a mucoadhesive preparation appears to promote better results
in the treatment/prevention of cytotoxic effects associated with
chemotherapy, as demonstrated here.
Azevedo et al. [27] observed that apolipoprotein E COG 133
mimetic peptide also restored the intestinal proliferative activ-
ity in the 5-FU-induced mucositis. In addition, the treatment
of mucositis-bearing mice with curcumin also modulated 5-FU-
induced apoptosis via reduction of Bax and caspase-3 together
with increase of Bcl-2 expression [28]. In another study, it was
shown that treatment of mucositis-bearing mice with a molecule
chemokine (C-X-C motif) ligand 9 (CXCL9), produced by interferon-
stimulated mononuclear cells, was also able to attenuate the
5-FU-induced weight loss as well as capable to promote the
recovery of the weight [29]. In this respect, treatment with the
mucoadhesive formulation containing BP/CL up modulated Ki-67
and Bcl-2 expression while reduced pro-apoptotic regulator Bax. In
parallel, the inﬂammatory response triggered by 5-FU was dimin-
ished by reducing 68% of myeloperoxidase activity and increasing
IL-10 levels. The formulation also reduced MDA  activity.
The activation of transcription nuclear factor-kB (NF-kB) exerts
a critical role in the increased production of pro-inﬂammatory
cytokines, responsible for ampliﬁcation in pathological pathways
of the chemotherapy-induced intestinal toxicity [30,31]. In addi-
tion to its role in immune response, NF-kB is also involved in
the regulation of key cellular genes of inﬂammation and cell pro-
liferation signaling pathways [32]. In this respect, Bo et al. [33]
showed that ﬂavonoids from Bidens bipinnata L. also promote
anti-inﬂammatory effects through inhibiting production of pro-
inﬂammatory cytokines (IL-8, TNF-) and nitric oxide levels as well
as suppression of NF-B and fractalkine expression.
Several natural products have drawn attention due to their abil-
ity to attenuate oxidative stress by inhibiting NF-kB activation as
demonstrated by the activity of curcumin in rat liver [34]. Fur-
thermore, the use of curcumin has been proposed in combination
with anticancer treatment to prevent the chemotherapy-induced
intestinal toxicity [35]. Thus, antioxidant and anti-inﬂammatory
properties of BP or CL were, at least in part, veriﬁed here corrobo-
rated with the ﬁndings widely reported in the literature [36,37].
Combined with their interesting protective effects, the low
oral systemic toxicity of the present mucoadhesive formulation
reafﬁrms its therapeutic potential in the treatment of intestinal
mucositis in a safe manner. In vivo studies have highlighted the
safe use of BP or CL in acute and subchronic toxicity studies in
rodents [38,39]. Moreover, in a clinical trial, the use of curcumi-
noids showed no adverse effects in patients with oral lichen planus,
an autoimmune mucocutaneous condition [40]. In another clin-
ical study, Elad et al. [16] have shown the use of a curcumin
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Fig. 5. Effects of non-mucoadhesive or mucoadhesive formulations containing BP/CL on the expression of apoptosis and cell proliferation markers in the intestinal tissue of
mucositis-bearing mice induced by 5-FU. Formulation doses or blank formulation were administered orally (gavage) to mice over 6 days, while doses of 5-FU (200 mg/kg)
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outhwash was also safe and well-tolerated. Furthermore, Cor-
en et al. [41] demonstrated that a botanical product containing BL
id not promote laboratory abnormalities and no adverse events
ere reported in a clinical study. It has also been reported that
P protects normal human erythrocytes from oxidative damage
42]. Other study has highlighted that essential oil from CL did not
hange the hematological parameters of rats as well as any chro-
osome aberration, DNA damage or micronuclei were observed in
heir bone marrow cells [43]. In this context, no changes in the fre-
uency of micronucleus induced by the formulation was observed.oup) were euthanized and the small intestine of each mice was collected for Ki-67,
ative of each treatment group. (**p < 0.01 and ***p < 0.001 vs. control; ##p < 0.01 and
In conclusion, this study showed important potential of the
mucoadhesive formulation of BP/CL for the treatment of 5-FU-
induced intestinal mucositis. Results showed that antioxidant
and anti-inﬂammatory activities are involved in the protective
pathways of BP/CL as well as their ability to modulate the prolif-
erative and apoptotic activity of intestinal framework compared
to the injury triggered by 5-FU. Given the perspectives for the
development of a new medicine, clinical studies are in progress
to better understand the protective effects of this innovative
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Fig. 6. Effects of the mucoadhesive formulation of BP/CL on the inﬂammatory and oxidative stress response-induced by 5-FU. Formulation doses or blank formulation
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